THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE PROPERTY OR PRIVILEGE IS CLAIMED ARE AS FOLLOWS:

1. A topically applied transdermally penetrating systemic independent acting pharmaceutical combination and formulation for the treatment of a disease or condition of the skin and exposed tissue for example, basal cell carcinoma, the precancerous, often recurrent, actinic keratoses lesions, fungal lesions, "liver" spots and like lesions (found for the most part in the epidermis), squamous cell tumours, metastatic cancer of the breast to the skin, primary and metastatic melanoma in the skin, genital warts (condyloma acuminata) cervical cancer, and HPV (Human Papilloma Virus) including HPV of the cervix, psoriasis (both plaque-type psoriasis and nail bed psoriasis), corns on the feet and hair loss on the head of pregnant women, comprising, together with pharmaceutical excipients suitable for topical application, a therapeutically effective non-toxic amount of a drug which inhibits prostaglandin synthesis administered with, or carried in, an amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and/or sub-units of hyaluronic acid (preferably hyaluronic acid and salts thereof) sufficient to facilitate the drug's penetration through the skin and tissue (including any scar tissue) at the site requiring treatment, to block prostaglandin synthesis.

2. The combination or formulation of Claim 1 wherein the drug is a non-steroidal anti-inflammatory drug (NSAID).

3. The combination or formulation of Claim 2 wherein the hyaluronic acid and/or salts thereof (for example, the sodium salt) and/or homologues, analogues, derivatives, complexes, esters, fragments, and/or sub-units of hyaluronic acid is hyaluronic acid or a salt thereof.

4. The formulation or combination of Claim 3 wherein the NSAID is selected from diclofenac, indomethacin, naproxen, and (+,-) tromethamine salt of ketorolac.

5. The formulation or combination of Claim 3 wherein the NSAID is selected from IBUPROFEN, PIROXICAM, Propionic Acid derivatives, aceytylsalicylic acid and Flunixin.

6. A method of treating a disease or condition of the skin and exposed tissue for example, basal cell carcinoma, the precancerous, often recurrent, actinic keratoses lesions, fungal lesions, "liver" spots and like lesions (found for the most part in the epidermis), squamous cell tumours, metastatic cancer of the breast to the skin, primary and metastatic melanoma in the skin, genital warts (condyloma acuminata) cervical cancer, and HPV (Human Papilloma Virus) including HPV of the cervix, psoriasis (both plaque-type psoriasis and nail bed psoriasis), corns on the feet and hair loss on the head of pregnant women, in a mammal which comprises administering topically to the mammal a combination comprising, together with pharmaceutical excipients suitable for topical application, a therapeutically effective (to treat and resolve the disease, condition or lesion), non-toxic (to the patient) amount of a drug which inhibits prostaglandin synthesis administered with, or carried in, an

amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and/or sub-units of hyaluronic acid sufficient to facilitate the drug's penetration through the skin and tissue (including any scar tissue) at the site to be treated to block prostaglandin synthesis.

7. The method of Claim 6 wherein the treatment is applied daily for a number of weeks.

Sub B3

8. The method of Claim 6 wherein the hyaluronic acid and salts thereof (for example, the sodium salt) and/or homologues, analogues, derivatives, complexes, esters, fragments, and/or sub-units of hyaluronic acid is hyaluronic acid or a salt thereof.

9. The method of Claim 8 wherein the drug is a non-steroidal anti-inflammatory drug (NSAID).

Sub B4

10. The method of Claim 9 wherein the NSAID is selected from diclofenac, indomethacin, naproxen, and (+,-) tromethamine salt of ketorolac.

11. The method of Claim 9 wherein the NSAID is selected from IBUPROFEN, PIROXICAM, Propionic Acid derivatives, aceytylsalicylic acid and Flunixin.

12. The method of Claim 7 wherein the hyaluronic acid and salts thereof (for example, the sodium salt) and/or homologues, analogues, derivatives, complexes, esters, fragments, and/or

sub-units of hyaluronic acid is hyaluronic acid or a salt thereof.

13. The method of Claim 12 wherein the drug is a non-steroidal anti-inflammatory drug (NSAID).

14. The method of Claim 13 wherein the NSAID is selected from diclofenac, indomethacin, naproxen, and (+,-) tromethamine salt of ketorolac.

15. The method of Claim 13 wherein the NSAID is selected from IBUPROFEN, PIROXICAM, Propionic Acid derivatives, aceytylsalicylic acid and Flunixin.

16. Transdermal delivery of a therapeutically effective amount of a drug which prohibits prostaglandin synthesis applied topically to treat a disease or condition of the skin and exposed tissue for example, basal cell carcinoma, the precancerous, often recurrent, actinic keratoses lesions, fungal lesions, "liver" spots and like lesions (found for the most part in the epidermis), squamous cell tumours, metastatic cancer of the breast to the skin, primary and metastatic melanoma in the skin, genital warts (condyloma acuminata) cervical cancer, and HPV (Human Papilloma Virus) including HPV of the cervix, psoriasis (both plaque-type psoriasis and nail bed psoriasis), corns on the feet and hair loss on the head of pregnant women, in a mammal, the delivery comprising administering topically a therapeutically effective (to treat the disease or condition of the skin or exposed tissue) non-toxic (to the patient) amount of such drug with a sufficient amount of hyaluronic acid and/or

salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and sub-units of hyaluronic acid sufficient to transport, or facilitate the transport of, the drug to the site to block prostaglandin synthesis.

17. The delivery of Claim 16 wherein the hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and sub-units of hyaluronic acid, preferably hyaluronic acid and salts thereof is selected from hyaluronic acid and/or salts thereof.

18. The delivery of Claim 17 wherein the drug is a non-steroidal anti-inflammatory agent (NSAID).

19. The delivery of Claim 18 wherein the NSAID is selected from diclofenac, indomethacin, naproxen, and (+,-) tromethamine salt of ketorolac.

20. The delivery of Claim 18 wherein the NSAID is selected from IBUPROFEN, PIROXICAM, Propionic Acid derivatives, aceytylsalicylic acid and Flunixin.

21. Use of a combination or formulation to treat a disease or condition of the skin and exposed tissue for example, basal cell carcinoma, the precancerous, often recurrent, actinic keratoses lesions, fungal lesions, "liver" spots and like lesions (found for the most part in the epidermis), squamous cell tumours, metastatic cancer of the breast to the skin, primary and metastatic melanoma in the skin, genital warts (condyloma acuminata) cervical cancer, and HPV (Human Papilloma

Virus) including HPV of the cervix, psoriasis (both plaque-type psoriasis and nail bed psoriasis), corns on the feet and hair loss on the head of pregnant women, the combination and formulation comprising, together with pharmaceutical excipients suitable for topical application, a therapeutically effective (to treat and resolve the condition or disease of the skin or exposed tissue), non-toxic (to the patient) amount of a drug which inhibits prostaglandin synthesis administered with, or carried in, an amount of hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and/or sub-units of hyaluronic acid sufficient to facilitate the drug's penetration through the skin and tissue (including any scar tissue) at the site to be treated to block prostaglandin synthesis.

22. The use of Claim 21 wherein the hyaluronic acid and/or salts thereof and/or homologues, analogues, derivatives, complexes, esters, fragments, and sub-units of hyaluronic acid, preferably hyaluronic acid and salts thereof is selected from hyaluronic acid and/or salts thereof.

23. The use of Claim 21 wherein the drug is a non-steroidal anti-inflammatory agent (NSAID).

24. The use of Claim 23 wherein the NSAID is selected from diclofenac, indomethacin, naproxen, and (+,-) tromethamine salt of ketorolac.

25. The use of Claim 23 wherein the NSAID is selected from IBUPROFEN, PIROXICAM, Propionic Acid derivatives, aceytylsalicylic acid and Flunixin.